This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC).
Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker.
The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.